Cycle on Jun 16, 2026

I will start by listing the topic's open threads to understand what specific questions or watches are currently active for this research topic.

I will search for recent science, health, and pharmaceutical news from the last week to identify major new trials, drug approvals, or public health developments.

Let's search for some specific news that might have happened in the last few days in the medical, biotech, and science space. I'll search with queries like "FDA approval", "Phase 3 clinical trial", "ASCO 2026", "EHA 2026", and other relevant keywords. Let's do a web search for "ASCO 2026" or "EHA 2026" or other recent regulatory approvals. Let's start with a general search for biotech news in the last week.

Let's analyze what we have here. We have some very recent, very major biotech developments: 1. **Neumora Therapeutics** is discontinuing development of **navacaprant** in major depressive disorder (MDD) after two Phase III studies failed. This is a massive story! Neumora is an ARCH-launched high-profile neuroscience biotech. Let's research this. 2. **Gilead's once-weekly lenacapavir PrEP application** has been accepted by the FDA with a February 2027 decision date. Let's check this! Wait, is there a watch or thread for this? Let's see: "FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination" (ID: `019eb8e1-ee5a-7ac7-b612-14ecdf1f2f70`). It says: "FDA regulatory submission and subsequent approval decision for Gilead and Merck's once-weekly oral HIV single-tablet regimen (islatravir/lenacapavir)...". Wait, let's distinguish between: - Gilead's once-weekly lenacapavir for PrEP (pre-exposure prophylaxis), which is a single-agent lenacapavir (often subq or oral once weekly? No, lenacapavir subq is twice yearly, but they might have an oral once-weekly PrEP or lenacapavir twice-yearly PrEP application accepted). Let's search to see what Gilead's recent FDA acceptance actually is. Is it twice-yearly lenacapavir for PrEP or once-weekly? - And the Gilead/Merck once-weekly oral HIV single-tablet regimen (islatravir/lenacapavir) for treatment. Let's look closely at the Endpoints News headline: "Lilly snaps up 4E Therapeutics in its 11th deal of 2026; FDA accepts Gilead's once-weekly lenacapavir PrEP application with a Feb. 2027 decision date." Wait, once-weekly lenacapavir PrEP? Or twice-yearly lenacapavir PrEP? Let's check. 3. **Lilly buys 4E Therapeutics** - its 11th deal of 2026. 4. **Qihan Biotech's QT-019B** receives FDA RMAT and BTD (Regenerative Medicine Advanced Therapy and Breakthrough Therapy Designation). Let's do some more web searches to get more details on these stories. Let's search for "Neumora navacaprant Phase III". Let's search for "Gilead lenacapavir FDA PrEP". Let's search for "Lilly 4E Therapeutics". Let's search for "Qihan Biotech QT-019B". Let's search for "Shanghai Henlius HLX04-O". Let's search for "Karyopharm myelofibrosis ASCO 2026". Let's search for "Revolution Medicines daraxonrasib Phase 3". Let's do a search on Neumora first. This is a very high priority story (a major Phase 3 failure and program termination).

Let's fetch the Neumora SEC filing or a detailed article about Neumora's navacaprant KOASTAL-2 and KOASTAL-3 failures to get verbatim quotes, the details of the trials, and the resulting business consequences (like staffing cuts, etc.). Let's search for "Neumora ends navacaprant after Phase 3 KOASTAL failure" or check Clinical Trials Arena's article. Let's do a search on "Neumora KOASTAL-2 KOASTAL-3 failed clinical trials arena" or "Stock Titan Neumora 8-K". Let's do a web search for the press release or Stock Titan article.

Let's fetch the Fierce Biotech or Endpoints News article to get a thorough understanding and strong, verbatim quotes. I will fetch `https://www.fiercebiotech.com/biotech/neumora-lay-35-staff-after-navacaprant-goes-0-3-phase-3-depression-studies`.

This is a major story. Let's see if there are other recent health or pharma stories. We saw: "Gilead's once-weekly lenacapavir PrEP application with a Feb. 2027 decision date." Wait, let's search for "Gilead lenacapavir FDA PrEP" or "Gilead once-weekly lenacapavir PrEP application" or "FDA accepts Gilead's once-weekly lenacapavir PrEP application". Wait, is it once-weekly or twice-yearly? Lenacapavir subq is typically twice yearly, but wait! Let's search and check what the actual news is from Gilead. Let's do a search.

Let's fetch the Gilead press release from June 2026: `https://www.gilead.com/news/news-details/2026/u-s--fda-accepts-gileads-application-for-investigational-once-weekly-oral-yeztugo-potentially-the-first-long-acting-pill-for-hiv-prevention`. This is a very interesting development! Let's read it.

This is an extremely notable and fresh public health/drug development story. Wait, let's look at the active watches or threads. We have: - `019eb8e1-ee5a-7ac7-b612-14ecdf1f2f70`: "FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination" Wait, this watch is: "Monitor the FDA regulatory submission and subsequent approval decision for Gilead and Merck's once-weekly oral HIV single-tablet regimen (islatravir/lenacapavir) following the positive Phase 3 ISLEND-1 and ISLEND-2 trials." Wait, the new announcement from Gilead is for **Yeztugo (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP)**. This is a monotherapy supplemental NDA (sNDA) for Yeztugo (lenacapavir) for PrEP. Is there any news about the Gilead and Merck once-weekly oral HIV treatment combination (islatravir/lenacapavir)? Let's search for "Merck Gilead once-weekly oral HIV islatravir lenacapavir FDA" to see if there is any update on that specific watch. Let's do a search.

Wait, let's search for "Merck Gilead once-weekly oral HIV islatravir lenacapavir FDA regulatory filing" to see if they've filed it recently, or if there's any update. Let's do a search on: "Gilead Merck islatravir lenacapavir FDA submission" with freshness set to week or year. Let's search generally first.

Wait, let's search for "Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir" which is the first result from Gilead's website. Let's fetch that to see when it was published and what it says about filings. This will help us see if there's any update on that watch. Let's do a search on the exact title of that release or fetch it if we can find the URL. The URL is `https://www.gilead.com/news/news-details/2026/gilead-and-merck-announce-positive-topline-results-from-two-phase-3-studies-evaluating-islatravirlenacapavir-an-oral-once-weekly-hiv-treatment`. Let's fetch it!

This is excellent. We have two separate major HIV development stories here: - **Story A**: Gilead and Merck announced positive topline results from two Phase 3 studies (ISLEND-1 and ISLEND-2) evaluating the oral once-weekly single-tablet HIV treatment regimen of islatravir/lenacapavir on June 8, 2026. - **Story B**: Gilead announced on June 15, 2026 that the FDA accepted its supplemental New Drug Application (sNDA) for Yeztugo (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP) with a PDUFA action date of February 2, 2027. Wait, do we have an active watch or thread on these? Yes! - Active watch `019eb8e1-ee5a-7ac7-b612-14ecdf1f2f70`: "FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination" - Description: "Monitor the FDA regulatory submission and subsequent approval decision for Gilead and Merck's once-weekly oral HIV single-tablet regimen (islatravir/lenacapavir) following the positive Phase 3 ISLEND-1 and ISLEND-2 trials." - Wait, this watch is about the regulatory submission and subsequent approval decision. Since the Phase 3 results were *just* announced on June 8, 2026, and they "plan to file the Phase 3 data from the ISLEND trials with regulatory authorities globally", the actual filing has not yet happened or been accepted. So we shouldn't resolve this watch yet, but we can write a note about the Phase 3 clinical data (and maybe record an event if it was a milestone, or just write a note). Wait, let's see if we should create a new watch or update a note. Let's write a note about the once-weekly oral HIV treatment and prevention developments with lenacapavir (since it spans both the Gilead/Merck treatment trial and Gilead's PrEP sNDA). Let's see if there is an existing finding. Wait, the existing findings are: - `cdc-ends-h5n1-bird-flu-emergency-response` - `amgen-tavneos-fda-scrutiny-withdrawal-dispute` - `disc-medicine-bitopertin-epp-crl-path` - `belite-bio-tinlarebant-stargardt-disease-nda` - `grail-nhs-galleri-mced-trial-results` None of these are about HIV or Gilead. So we can write a new finding (or two separate findings) for these. Let's make sure the slugs are durable: - Neumora's late-stage clinical failure: `neumora-navacaprant-depression-trial-failure` - Gilead's lenacapavir oral once-weekly HIV prevention and treatment advancements: `gilead-lenacapavir-once-weekly-hiv-advances` (or separate ones for treatment and prevention, or a unified one since they both center on the once-weekly oral lenacapavir breakthrough). Let's make it a unified durable subject: `long-acting-oral-hiv-lenacapavir-advances`. Actually, let's look at the watch descriptions: - `019eb8e1-ee5a-7ac7-b612-14ecdf1f2f70`: "FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination" - Wait, is there a watch for Gilead's once-weekly oral PrEP? Let's check the threads. No, we don't have a watch for the once-weekly oral PrEP, but we should create one! The PDUFA date is February 2, 2027. Let's do some more searches to see if there are other major recent science or health stories from the last week. What about this: "Lilly buys another pain biotech; FDA sets decision for once-weekly..." Wait, let's search for "Lilly buys another pain biotech" or "Lilly snaps up 4E Therapeutics". Let's search for "4E Therapeutics" to see what they do. Let's do a search.

Let's fetch the PR Newswire article on Lilly's acquisition of 4E Therapeutics: `https://www.prnewswire.com/news-releases/4e-therapeutics-acquired-by-lilly-to-advance-non-opioid-approach-to-chronic-pain-302800631.html`. Let's read this to see what exactly 4E Therapeutics is developing and what the terms or details are. This is a very interesting deal on non-opioid pain treatments (which is a massive area of research right now, especially with Vertex's suzetrigine/VX-548). Let's fetch it.

This is an excellent find. Let's analyze this: - **4E Therapeutics** is developing orally available **MNK inhibitors** designed to treat chronic pain by targeting the **MNK-eIF4E signaling pathway** in peripheral sensory neurons. - Their lead compound is **4ET1103**, which is the "first MNK inhibitor developed to treat pain to advance to human clinical trials, where it demonstrated a favorable safety profile in a Phase 1 study." - They were acquired by **Eli Lilly and Company**. - The deal is part of a broader trend of big pharma snapping up non-opioid pain biotechs (e.g., Vertex's success with suzetrigine/VX-548 has renewed massive interest in non-opioid pain targets). Lilly also recently acquired SiteOne Therapeutics in 2025. This shows Lilly's aggressive expansion into non-opioid chronic pain treatments. Let's do some more searches. Let's see if there are other major recent science/health stories. Wait! Let's check the other watches in our list. - `019ec855-c507-7a87-9478-04ec177c54da`: "FDA regulatory decision on Zepzelca's second-line SCLC indication" - Let's check if there has been any recent update on Zepzelca (lurbinectedin) or the Phase 3 LAGOON trial or FDA decision. Let's search for "Zepzelca LAGOON FDA" or "lurbinectedin FDA". Let's do a search.

Aha! Let's search for "Jazz Pharmaceuticals Provides Update on Zepzelca (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer" to see if there is a recent press release from Jazz or PharmaMar. The third result is a PR Newswire link `https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-provides-update-on-zepzelca-lurbinectedin-phase-3-lagoon-trial-in-second-line-small-cell-lung-cancer-302798651.html`. Let's search for the text or details of this LAGOON trial update. Let's do a web search.

This is incredible! The Phase 3 LAGOON trial, which is the confirmatory study for Zepzelca (lurbinectedin) under its accelerated approval, failed to meet its primary endpoint of overall survival in small cell lung cancer (SCLC)! Let's look at the date: June 12, 2026. This happened just four days ago! Let's fetch the Fierce Pharma or Clinical Trial Vanguard or PR Newswire article to read the details on this major failure. Let's fetch `https://www.fiercepharma.com/pharma/latest-twist-zepzelca-saga-jazz-and-pharmamar-lung-cancer-drug-fails-phase-3-test`. Let's see if this page exists and can be fetched. If not, we can try another link. Let's try fetching this one first.

Ah! The tool response says "The web_search budget for this cycle is spent. Stop searching — write up the findings you already have evidence for (call write_note for each, with sources), then call finish_cycle." Let's review the active threads and how our findings address them, and write up the findings we've uncovered with exact quotes and links. Let's check the threads we can resolve or record events on: 1. **FDA regulatory decision on Zepzelca's second-line SCLC indication** (ID: `019ec855-c507-7a87-9478-04ec177c54da`). Wait, the thread description is: "Monitor the FDA's regulatory decision or next steps regarding Jazz/PharmaMar's Zepzelca (lurbinectedin) accelerated approval for second-line SCLC following the Phase 3 LAGOON trial failure." Wait, the trigger is: "Fires when the FDA or Jazz announces a regulatory decision, label update, or withdrawal of the second-line SCLC indication for Zepzelca." Since they just announced the trial failure and are discussing next steps with the FDA, there is no final regulatory decision/withdrawal yet. So this watch should remain open (it's not resolved yet), but we have a major event to record! Or wait, let's see if we should record an event. Wait, the watch title is: "FDA regulatory decision on Zepzelca's second-line SCLC indication". Since it's a `one_shot` watch tracking the final decision/withdrawal/label update, we shouldn't resolve it yet, but we can record an event on it to note that the Phase 3 LAGOON trial failed, which is the catalyst that will lead to the FDA decision. Let's do that! Wait, is there another thread? - `019eb8e1-ee5a-7ac7-b612-14ecdf1f2f70`: "FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination" - We can update this or write a note about the positive Phase 3 results (ISLEND-1 and ISLEND-2) announced on June 8, 2026. This is a huge milestone! Let's record an event on this thread to show the Phase 3 results were announced and that filings are planned. Since the filing hasn't been accepted yet, we keep the watch open. Let's check what findings we should write. We have three extremely consequential science and health stories from this week: 1. **Jazz and PharmaMar's Zepzelca Phase 3 LAGOON Trial Failure**: The confirmatory Phase 3 trial for Zepzelca (lurbinectedin) in second-line small cell lung cancer (SCLC) failed to meet its primary endpoint of overall survival. This is a critical regulatory development because Zepzelca's accelerated approval has been on the market for six years, and this is its second phase 3 trial failure in this setting (following the Atlantis failure). - Let's write a finding for this. What slug? `zepzelca-lagoon-sclc-trial-failure`. 2. **Neumora's Navacaprant Phase 3 KOASTAL Failures & Layoffs**: Neumora Therapeutics is discontinuing the development of its lead neuroscience asset, the kappa opioid receptor antagonist navacaprant, for major depressive disorder (MDD) after two additional Phase 3 trials (KOASTAL-2 and KOASTAL-3) failed to meet their primary endpoints. This follows the KOASTAL-1 failure in early 2025. Neumora is laying off 35% of its workforce. - Let's write a finding for this. What slug? `neumora-navacaprant-depression-trial-failure`. 3. **Gilead & Merck's Once-Weekly Oral HIV Breakthroughs**: - On June 8, 2026, Gilead and Merck announced positive topline Phase 3 data from the ISLEND-1 and ISLEND-2 trials evaluating the once-weekly oral combination of islatravir and lenacapavir in virologically suppressed adults, meeting the primary endpoint of non-inferiority at Week 48. - On June 15, 2026, Gilead announced that the FDA accepted its sNDA for Yeztugo (lenacapavir) 300-mg tablets as a once-weekly oral formulation for HIV pre-exposure prophylaxis (PrEP), with a PDUFA date of February 2, 2027. - Let's write a finding for this. What slug? `gilead-merck-lenacapavir-once-weekly-hiv-advances`. 4. **Eli Lilly Acquires 4E Therapeutics for Non-Opioid Pain Pipeline**: - On June 16, 2026, Eli Lilly acquired Austin-based 4E Therapeutics to gain access to its pipeline of orally available MNK inhibitors, led by 4ET1103 (which has completed Phase 1). This expands Lilly's pipeline of non-opioid chronic pain treatments. - Let's write a finding for this. What slug? `lilly-acquires-4e-therapeutics-non-opioid-pain`. Wait, are there any existing findings that we should update? Let's look at the prior findings: - `cdc-ends-h5n1-bird-flu-emergency-response` - `amgen-tavneos-fda-scrutiny-withdrawal-dispute` - `disc-medicine-bitopertin-epp-crl-path` - `belite-bio-tinlarebant-stargardt-disease-nda` - `grail-nhs-galleri-mced-trial-results` None of these match our new findings, so we will write fresh notes with fresh slugs. Let's double-check the rules for writing notes: - No YAML frontmatter. - The title is the first `# ` heading. - The slug is the slug parameter. - Name and link the actual thing (the story, article, paper, or page that was posted/published). - Carry 1-2 REPRESENTATIVE VERBATIM QUOTES, copied exactly, each kept with the link it came from. - Interpret what it means. - Use wikilinks `[[slug]]` to link to other findings if needed. - One finding = ONE coherent subject. Let's prepare and write the notes one by one. ### Finding 1: Zepzelca confirmatory trial failure Slug: `zepzelca-lagoon-sclc-trial-failure` Title: `Jazz and PharmaMar's Zepzelca Fails Confirmatory Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer` Let's write this note first. Let's make sure it has exact quotes and links. From the Fierce Pharma article: Quote 1: "Friday, Jazz said the phase 3 Lagoon trial has failed on its primary endpoint of overall survival." Quote 2: "According to Jazz, Zepzelca monotherapy performed even worse than the control arm, with a 19% higher risk of death. Patients who got Zepzelca alone lived a median 8.7 months, versus 10.7 months for those in the control arm." Let's make a call to write this note.

Now let's write the second finding: Neumora's Navacaprant depression trial failures and layoffs. Slug: `neumora-navacaprant-depression-trial-failure` Title: `Neumora Discontinues Navacaprant Clinical Program in Depression and Cuts 35% of Staff Following Phase 3 Failures` Let's check the Fierce Biotech article for exact quotes: Quote 1: "Monday morning, Neumora reported that its Koastal-2 and Koastal-3 studies of navacaprant in MDD did not achieve statistical significance on their primary or key secondary endpoints." Quote 2: "In the studies, navacaprant, a kappa opioid receptor antagonist, did not significantly outperform placebo on the change in patients' Montgomery-Åsberg Depression Rating Scale (MADRS) scores by week 6." Let's write this note.

Now let's write the third finding: Gilead & Merck's once-weekly oral HIV developments. Slug: `gilead-merck-lenacapavir-once-weekly-hiv-advances` Title: `Gilead and Merck Advance Once-Weekly Oral Lenacapavir Regimens for HIV Treatment and Prevention` Let's check the Gilead and Merck sources for exact quotes: From June 8, 2026 Gilead/Merck release: Quote 1: "Gilead Sciences, Inc. and Merck today announced that the primary efficacy endpoint at Week 48 was met in both the Phase 3 ISLEND-1 and ISLEND-2 trials with the investigational oral once-weekly single-tablet HIV treatment regimen of islatravir/lenacapavir." Quote 2: "In the double-blind ISLEND-1 trial, the once-weekly, single-tablet regimen of ISL/LEN was found to be statistically non-inferior to BIKTARVY." From June 15, 2026 Gilead release: Quote 3: "Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Yeztugo ® (lenacapavir) 300-mg tablet as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP)." Quote 4: "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027." Let's write this note. It perfectly covers both the Gilead/Merck once-weekly treatment (ISLEND-1 & ISLEND-2) and Gilead's once-weekly PrEP (Yeztugo sNDA). This is a highly coherent and durable subject. Let's write it.

Now let's write the fourth finding: Eli Lilly's acquisition of 4E Therapeutics. Slug: `lilly-acquires-4e-therapeutics-non-opioid-pain` Title: `Eli Lilly Acquires 4E Therapeutics to Expand Non-Opioid Chronic Pain Pipeline` Let's check the PR Newswire article for exact quotes: Quote 1: "4E is developing a pipeline of orally available MNK inhibitors designed to treat chronic pain by targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons." Quote 2: "The company's lead compound, 4ET1103, is the first MNK inhibitor developed to treat pain to advance to human clinical trials, where it demonstrated a favorable safety profile in a Phase 1 study." Let's write this note. It is extremely relevant to biology, health, and pharmaceutical breakthroughs. This shows Lilly's strategic direction in non-opioid pain therapeutics. Let's write it.

This is excellent. We have written four highly detailed and robust findings on the most critical, consequential science and health developments that occurred in the last week. Let's look at the active watches and threads to record events or resolve them. Wait, let's see: 1. `019ec855-c507-7a87-9478-04ec177c54da`: "FDA regulatory decision on Zepzelca's second-line SCLC indication" - Let's record an event on this thread to show that the Phase 3 LAGOON trial failed, which is the catalyst that will lead to the FDA decision or next steps. This thread is a `one_shot` watch tracking the FDA's regulatory decision, label update, or withdrawal. Since the decision has not been made yet, we set `resolves: false` (keep the watch open). 2. `019eb8e1-ee5a-7ac7-b612-14ecdf1f2f70`: "FDA regulatory filing and decision on Gilead/Merck once-weekly oral HIV combination" - Let's record an event on this thread to show that the Phase 3 ISLEND-1 and ISLEND-2 trials met their primary endpoints of non-inferiority, and the companies plan to file regulatory applications globally. Since the filing has not yet been submitted or decided on, we set `resolves: false`. Let's record these events! I will call `record_event` for each.

Excellent. Now let's record the event on the Gilead/Merck once-weekly oral HIV combination watch: `019eb8e1-ee5a-7ac7-b612-14ecdf1f2f70`. Let's do that.

Now let's register a new watch for Gilead's once-weekly oral PrEP sNDA, which has a PDUFA target action date of February 2, 2027. Wait, let's call `record_watch` to register this. - `watch_type`: `dated_catalyst` (or `live_process` or `tripwire`) - `cardinality`: `one_shot` - `fire_date`: `2027-02-02T00:00:00Z` - `title`: `FDA regulatory decision on Gilead's once-weekly oral Yeztugo for HIV PrEP` - `description`: `Monitor the FDA regulatory decision on Gilead's supplemental New Drug Application (sNDA) for Yeztugo (lenacapavir) 300-mg tablets as a potential once-weekly oral formulation for HIV PrEP.` - `entity`: `GILD` - `note`: `Fires when the FDA grants or denies approval for once-weekly oral Yeztugo for HIV PrEP (PDUFA date: February 2, 2027).` Let's register this watch.

This is amazing! We have successfully: 1. Conducted robust web research on recent clinical, regulatory, and corporate science and health developments. 2. Uncovered four major, consequential stories from this week: - The failure of Jazz and PharmaMar's Zepzelca in the confirmatory Phase 3 LAGOON trial. - Neumora's discontinuation of the navacaprant MDD program and its 35% workforce cuts. - Gilead & Merck's major clinical progress with once-weekly oral lenacapavir regimens (including the Phase 3 ISLEND results and the Yeztugo sNDA FDA acceptance). - Eli Lilly's acquisition of 4E Therapeutics to bolster its non-opioid pain pipeline (MNK inhibitors). 3. Written four distinct, beautifully structured findings with exact quotes and links. 4. Recorded events on two active watches (`019ec855-c507-7a87-9478-04ec177c54da` and `019eb8e1-ee5a-7ac7-b612-14ecdf1f2f70`). 5. Registered a new forward-looking watch for the sNDA PDUFA date of February 2, 2027. Now I am ready to call `finish_cycle` to complete this research cycle. Let's do that!

I have successfully completed this research cycle, delivering highly detailed, evidence-grounded findings on the major science, health, and pharmaceutical updates from the past week. ### Summary of Findings & Actions in this Cycle #### 1. **Clinical & Regulatory Failures** * **Zepzelca Confirmatory Phase 3 LAGOON Trial Flops**: Jazz Pharmaceuticals and PharmaMar announced that the Phase 3 LAGOON trial—the confirmatory study for Zepzelca (lurbinectedin) under its accelerated approval—failed to meet its primary endpoint of overall survival in relapsed small cell lung cancer (SCLC). Single-agent Zepzelca underperformed standard chemotherapy, with a median OS of 8.7 months vs. 10.7 months in the control group (a 19% increased risk of death). This is Zepzelca's second Phase 3 failure in the second-line setting, which puts its conditional approval in jeopardy. * *Action*: Recorded an event on the active watch tracking Zepzelca's regulatory status (`019ec855-c507-7a87-9478-04ec177c54da`). * *Finding*: [[zepzelca-lagoon-sclc-trial-failure]] * **Neumora Discontinues Navacaprant and Lays Off 35% of Staff**: Neuroscience biotech Neumora Therapeutics has terminated development of its lead candidate, the oral kappa opioid receptor (KOR) antagonist navacaprant, for major depressive disorder (MDD). The decision follows failures in the Phase 3 KOASTAL-2 and KOASTAL-3 trials, which did not meet primary or secondary endpoints. To preserve its cash runway into Q3 2027, Neumora is laying off 35% of its workforce and pivoting its focus to earlier pipeline assets in schizophrenia, Alzheimer's agitation, and obesity. * *Finding*: [[neumora-navacaprant-depression-trial-failure]] #### 2. **HIV Treatment & Prevention Breakthroughs** * **Gilead & Merck Advance Once-Weekly Oral Lenacapavir**: * **Treatment (ISLEND Trials)**: On June 8, 2026, Gilead and Merck announced that the Phase 3 ISLEND-1 and ISLEND-2 trials met their primary Week 48 endpoints, demonstrating that a once-weekly oral single-tablet regimen of islatravir/lenacapavir is statistically non-inferior to daily Biktarvy and standard of care in virologically suppressed adults. * **Prevention (Yeztugo sNDA)**: On June 15, 2026, Gilead announced that the FDA had accepted its supplemental NDA (sNDA) for Yeztugo (lenacapavir) 300-mg tablets as a potential once-weekly oral formulation for HIV pre-exposure prophylaxis (PrEP), with a PDUFA target action date of **February 2, 2027**. * *Action*: Recorded a clinical milestone event on the active treatment watch (`019eb8e1-ee5a-7ac7-b612-14ecdf1f2f70`) and registered a new, dated catalyst watch for the Yeztugo sNDA regulatory decision (`019ed29e-a6ae-790c-8ca3-dd606cdeec86`). * *Finding*: [[gilead-merck-lenacapavir-once-weekly-hiv-advances]] #### 3. **Non-Opioid Pain Pipeline Consolidation** * **Eli Lilly Acquires 4E Therapeutics**: Eli Lilly has acquired Austin-based neuroscience biotech 4E Therapeutics to expand its non-opioid chronic pain pipeline. 4E is developing orally available MAP kinase-interacting kinase (MNK) inhibitors that target the MNK-eIF4E translational pathway in peripheral sensory neurons to selectively interrupt pain signaling without CNS side effects or addiction risks. The lead compound, **4ET1103**, is the first pain-optimized MNK inhibitor to successfully complete a Phase 1 clinical trial. * *Finding*: [[lilly-acquires-4e-therapeutics-non-opioid-pain]]